当前位置:首页 - 行情中心 - 康泰生物(300601) - 财务分析 - 现金流量表

康泰生物

(300601)

  

流通市值:130.73亿  总市值:162.18亿
流通股本:9.00亿   总股本:11.17亿

现金流量表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金498,322,841.572,869,059,868.951,981,526,371.411,227,569,112.81
  收到其他与经营活动有关的现金43,623,746.28124,817,870.373,091,000.5755,930,211.51
  经营活动现金流入小计541,946,587.852,993,877,739.252,054,617,371.981,283,499,324.32
  购买商品、接受劳务支付的现金113,540,886.07403,960,940.95263,717,833.14173,472,752.58
  支付给职工以及为职工支付的现金125,610,047.61501,429,663.51383,721,957.42267,864,630.99
  支付的各项税费44,061,413.72125,526,448.6888,246,884.1965,085,077.05
  支付其他与经营活动有关的现金358,010,138.781,327,391,400.75956,467,397.5701,480,111.3
  经营活动现金流出小计641,222,486.182,358,308,453.891,692,154,072.251,207,902,571.92
  经营活动产生的现金流量净额-99,275,898.33635,569,285.36362,463,299.7375,596,752.4
二、投资活动产生的现金流量:
  收回投资收到的现金614,000,0004,202,800,0002,091,800,000834,000,000
  取得投资收益收到的现金22,401,308.45195,606,986.98152,249,834.4533,674,638.36
  处置固定资产、无形资产和其他长期资产收回的现金净额350,000304,22553,22546,800
  投资活动现金流入小计636,751,308.454,398,711,211.982,244,103,059.45867,721,438.36
  购建固定资产、无形资产和其他长期资产支付的现金130,390,235.51331,922,832.18203,515,398.79159,983,023.59
  投资支付的现金470,000,0004,550,800,0011,366,800,001710,000,001
  支付其他与投资活动有关的现金59,317.3---
  投资活动现金流出小计600,449,552.814,882,722,833.181,570,315,399.79869,983,024.59
  投资活动产生的现金流量净额36,301,755.64-484,011,621.2673,787,659.66-2,261,586.23
三、筹资活动产生的现金流量:
  取得借款收到的现金11,000,00039,900,00039,900,00039,900,000
  收到其他与筹资活动有关的现金-11,765,606.1111,765,606.1184,357.78
  筹资活动现金流入小计11,000,00051,665,606.1151,665,606.1139,984,357.78
  偿还债务支付的现金-262,991,749.54248,591,749.54223,091,749.54
  分配股利、利润或偿付利息支付的现金7,091.94131,552,215.86131,552,215.86101,464,255.51
  支付其他与筹资活动有关的现金113,512.561,929,856.321,789,654.941,463,146.63
  筹资活动现金流出小计120,604.5396,473,821.72381,933,620.34326,019,151.68
  筹资活动产生的现金流量净额10,879,395.5-344,808,215.61-330,268,014.23-286,034,793.9
四、汇率变动对现金及现金等价物的影响-1,325,405.62-959,185.16-380,193.69-205,643.66
五、现金及现金等价物净增加额-53,420,152.81-194,209,736.61705,602,751.47-212,905,271.39
  加:期初现金及现金等价物余额221,859,517.84416,069,254.45416,069,254.45416,069,254.45
  期末现金及现金等价物余额168,439,365.03221,859,517.841,121,672,005.92203,163,983.06
补充资料:
  净利润-70,273,947.22-37,600,910.41
  资产减值准备-133,831,177.41-93,665,145.75
  固定资产和投资性房地产折旧-357,915,157-177,103,275.73
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-357,915,157-177,103,275.73
  无形资产摊销-42,445,592.57-22,193,837.92
  长期待摊费用摊销-33,020,003.17-22,497,376.09
  处置固定资产、无形资产和其他长期资产的损失-934,468.51-365,901.81
  固定资产报废损失-8,670,029.39-1,929,965.86
  公允价值变动损失--5,288,602.78--58,300
  财务费用-45,694,881.47-15,712,158.75
  投资损失--1,509,002.51--99,250.45
  递延所得税--24,809,822.75--37,722,832.42
  其中:递延所得税资产减少-8,136,199.37--35,306,967.37
    递延所得税负债增加--32,946,022.12--2,415,865.05
  存货的减少-49,176,851.48-6,306,540.69
  经营性应收项目的减少-159,186,275.04--148,527,495.63
  经营性应付项目的增加--276,354,777.12--143,174,781.72
  现金的期末余额-221,859,517.84-203,163,983.06
  减:现金的期初余额-416,069,254.45-416,069,254.45
  现金及现金等价物的净增加额--194,209,736.61--212,905,271.39
公告日期2026-04-222026-04-222025-10-282025-08-22
审计意见(境内)标准无保留意见
TOP↑